转录因子XBP1S基因表达谱差异分析

目的 应用基因表达谱芯片技术了解XBP1S在肝细胞中可能上调或下调的基因,了解其可能的调节功能线索.方法 构建pcDNA3.1（-）-XBP1S真核表达载体,转染HepG2细胞,同时以空载体pcDNA3.1（-）处理相同细胞系作为对照.48 h后制备细胞裂解液,提取mRNA,应用基因表达谱芯片技术对差异表达mRNA进行检测和分析.结果 构建的表达载体经过限制性内切酶分析和DNA序列测定,证实准确无误,提取高质量的总mRNA并进行逆转录成为cDNA,进行基因表达谱芯片技术分析.经过差异基因表达谱的筛选,发现HepG2细胞转染XBP1S以后,有38个基因表达水平显著上调,30个基因表达水平显著下调.结论 成功构建XBP1S的真核表达载体pcDNA3.1（-）-XBP1S,运用基因表达谱芯片技术成功筛选了XBP1S转染细胞后的差异表达基因,这些差异表达基因包括细胞周期、蛋白质的翻译合成及运输、能量代谢、体内免疫调节、细胞凋亡及细胞内的信号转导等方面起重要作用及肿瘤发生相关的基因,为进一步阐明XBP1S可能存在的调控机制及XBP1S蛋白可能的生物学功能提供理论依据.     

ABCA1对滋养细胞基因表达谱的影响

该文从基因学角度探讨了ABCA1对人滋养细胞功能的影响。在人滋养细胞中调控ABCA1的表达,通过表达谱芯片检测ABCA1表达改变后滋养细胞中基因及相关信号通路的改变,Western blot及qRT-PCR验证芯片结果。结果显示,上调ABCA1表达时,有197个基因表达升高,有190个基因表达下降;而下调ABCA1表达时,有335个基因表达升高, 459个基因表达下降。GO和KEGG分析表明, ABCA1表达上升或下降后可导致滋养细胞内多个信号通路发生改变。qRT-PCR及Western blot检测发现,与阴性对照组相比, ABCA1上调后细胞中S1PR1的m RNA及蛋白水平明显升高,而CCL8、CXCL10与CXCL11的mRNA及蛋白水平明显降低;下调ABCA1的表达后,细胞中S1PR1的mRNA及蛋白水平明显降低,而CCL8、CXCL10与CXCL11的mRNA及蛋白水平明显升高,与芯片的结果完全一致。这些结果表明, ABCA1可通过调控多个信号通路而影响滋养细胞功能。     

cDNA微阵列技术分析NAG7基因对鼻咽癌细胞基因表达谱的影响

运用cDNA微阵列技术分析NAG7基因重表达对HNE1细胞基因表达谱的影响.抽提HNE1细胞和pcDNA3.1(+)/NAG7/HNE1细胞总RNA,分离polyA mRNA,将mRNA逆转录为cDNA,并在逆转录过程中用³³P-dATP进行标记,与含有16 150个基因和表达序列标签(EST)的cDNA表达阵列膜杂交,获得基因表达图谱.Array Gauge软件分析NAG7基因的重表达所导致的鼻咽癌细胞HNE1基因表达谱改变,并用RNA印迹对微阵列杂交结果进行验证.结果分析表明,2倍以上的差异表达基因或EST 179个,其中表达上调的91个,表达下调的88个;已明确基因表达产物的上调基因29个,下调基因37个.在差异表达基因中,涉及基因转录调控、信号转导、细胞生长、细胞代谢和细胞凋亡等基因.RNA印迹证实生长阻滞特异蛋白1（gas 1）基因表达上调.特别值得关注的是, 先前的蛋白质组研究结果亦发现NAG7基因可导致生长阻滞特异蛋白1表达上调,说明gas 1基因在NAG7重表达的HNE1细胞中具有重要作用,这为深入研究NAG7基因的作用环节和机理提供了重要的线索.     

选择性COX-2抑制剂celecoxib对K562细胞的增殖抑制、凋亡诱导作用和分子机制

环氧化酶(cyclooxygenase, COX)家系被显示与恶性肿瘤的增殖和凋亡耐受有关,COX-2可作为恶性肿瘤治疗和预防的重要分子靶标.应用COX-2特异抑制剂——celecoxib,观察了药物对人慢性粒细胞白血病急变细胞株——K562细胞的增殖抑制和凋亡诱导效应.结果证明,celecoxib能够有效地抑制K562细胞增殖(台盼蓝染色,MTT试验及集落形成抑制试验证实),并呈一定的剂量依赖性.Celecoxib抑制K562细胞增殖的IC₅₀为46 μmol/L.通过DNA ladder胶电泳和流式细胞仪检测,凋亡细胞的AO/EB染色等方法证明celecoxib能够诱导K562细胞凋亡,这一效应与Caspase-3蛋白表达上调和裂解激活有关,当阻断Caspase-3的活性,celecoxib诱导的K562细胞凋亡明显受抑.利用RT-PCR分析技术及蛋白质印迹,证明K562细胞存在COX-2 mRNA和COX-2蛋白表达;而且,K562细胞COX-2蛋白表达可被IL-1β诱导性刺激,从而确认K562细胞为COX-2表达阳性细胞;celecoxib在较高浓度(80～160μmol/L)既可抑制K562细胞COX-2 mRNA表达,也可下调COX-2蛋白质表达,提示celecoxib抗K562白血病细胞活性与COX-2的抑制相关,其抗白血病的分子机制部分涉及到COX-2依赖性途径.     

应用蛋白质组学技术筛选胃癌SGC-7901细胞中的let-7a功能相关蛋白

为探讨let-7a表达下调在胃癌发病中的机制,高通量地检测了与let-7a功能相关的蛋白质.首先采用基因克隆技术稳定过表达SGC-7901细胞系的let-7a基因,然后用蛋白质组学技术研究稳定过表达该基因对SGC-7901细胞蛋白质表达谱的影响.通过对SGC-7901/let-7a细胞的蛋白质表达谱改变的研究,并用基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS)分析鉴定了10个差异表达蛋白质.这些差异表达蛋白质可能是let-7a功能相关蛋白质,其中抗氧化蛋白2、胰岛素样生长因子结合蛋白2、二硫化蛋白异构酶A2、四氢叶酸合成酶、细胞周期素依赖性激酶抑制蛋白1、Rho-GTPsae激活蛋白4表达上调,Skp2蛋白、血小板黏附蛋白CD41、纤维连接蛋白、Cks1蛋白表达下调.部分差异表达蛋白质如细胞周期素依赖性激酶抑制蛋白1、Skp2蛋白和纤维连接蛋白经蛋白质印迹分析进行了验证.在SGC-7901/let-7a中鉴定的10个差异表达蛋白质涉及到细胞周期的调控、分子基因表达调控、细胞黏附、细胞代谢等众多事件,它们可能作为let-7a功能相关蛋白质,为阐明let-7a表达下调在胃癌发病中的机制提供了重要线索.     

小鼠脑微血管内皮细胞与新生隐球菌GXM作用后基因表达谱分析

目的探索新生隐球菌GXM能否影响脑微血管内皮细胞基因的表达,为进一步研究隐球菌嗜中枢性的分子机制提供线索。方法使用Roche Nimble Gen 12×135K小鼠基因表达谱芯片,筛选小鼠脑微血管内皮细胞系b End.3与不同浓度新生隐球菌GXM作用后差异表达的基因;结合基因本体论(Gene Ontology),使用top GO进行差异基因GO分析,结合GO语义挖掘与隐球菌侵袭中枢神经系统能力相关的差异表达基因的信息;采用荧光实时定量PCR对重要基因PIK3C2G和ADAMDEC1的表达水平变化加以验证。结果 b End.3细胞与新生隐球菌GXM作用前后基因表达对比发现,实验组GXM(90μg/m)组总共有402个基因表达上调,296个基因表达下调,GXM(180μg/m)组总共有421个基因表达上调,564个基因表达下调,细胞膜、细胞骨架、磷酸肌醇-3-激酶活化、1-磷酸肌醇-3-激酶活化、细胞紧密连接等生物过程差异表达基因较为富集;对PIK3C2G基因和ADAMDEC1基因表达水平变化进行荧光定量PCR验证,结果与芯片结果一致,基因表达水平不同程度上升,且与GXM浓度正相关。结论新生隐球菌GXM能够影响脑微血管内皮细胞基因表达,PIK3C2G基因、ADAMDEC1基因表达上调可能和隐球菌穿越血脑屏障有关。     

蝎毒多肽提取物抑制DU- 145 细胞 COX- 2 和MMP- 9 表达的研究

目的：研究蝎毒多肽提取物（peptide extract from scorpion venom,PESV）对雄激素非依赖性人前列腺癌细胞株DU-145COX-2和MMP-9表达的影响,进一步探讨其抗血管生成的分子机制,为抗前列腺癌骨转移提供有效的治疗手段。方法：采用免疫组只化学方法检测PESV对COX-2、MMP-9蛋白表达的影响,应用RT-PCR检测PESV对MMP-9在mRNA水平表达的影响。结果：蝎毒多肽提取物（40μg／mL）作用于前列腺癌细胞后,COX-2、MMP-9蛋白表达水平明显下调（P〈0．05）,进一步检测发现MMP-9在mRNA水平亦明显下降（P〈0．05）。结论：蝎毒多肽提取物（PESV）通过抑制前列腺癌细胞血管生成因子COX-2的表达而发挥其抗血管生成作用,具有临床应用价值。     

小鼠脑微血管内皮细胞与隐球菌作用前后基因表达谱分析

目的 比较小鼠脑微血管内皮细胞系bEnd.3细胞与隐球菌作用前后基因表达谱的变化,为隐球菌的嗜中枢性研究提供新的线索.方法 采用基因芯片法比较bEnd.3细胞与不同血清型隐球菌作用前后基因表达谱的变化,并进一步通过荧光定量PCR的方法对某些重要基因的变化加以验证.结果 我们对bEnd.3与隐球菌作用前后基因表达进行了对比,共获得差异基因383条,其中263条基因表达下降,120条基因表达上升,并根据比较结果选取了黏附分子CDH 10及硒转运蛋白SELENBP 1两个基因进行荧光定量PCR验证,结果与芯片结果一致.发现bEnd.3与隐球菌作用后CDH 10表达明显下降,而SELENBP1表达明显上升.结论 隐球菌能引起脑血管内皮细胞黏附分子CDH 10表达下降及硒结合蛋白selenbp1表达上升,这可能与其侵袭血脑屏障有关.而SELENBP1的表达上升可能与神经系统症状有关.     

水稻病程相关蛋白质在逆境胁迫下的表达研究

植物病程相关(PR)基因一般在病原物侵染过程中受诱导发生转录上调．目前有证据提示植物PR基因在非生物逆境胁迫下也发生转录变化,但其蛋白质的表达变化情况还鲜有报道．为了解水稻PR蛋白质在逆境胁迫下的表达特征,本文采用免疫印迹技术(Western blotting,WB)调查了8个PR蛋白质在冷、热、旱、淹和盐等5种胁迫下的表达谱．结果表明：在冷胁迫下PR8表达上调,在热胁迫下PR1a、PR3、PR5和PR16表达下调;在旱胁迫下PR1a、PR2和PR8表达上调,而PR5 和PR16表达下调,在淹胁迫下PR1、PR2和PR15表达上调,PR1a、PR3、PR5和PR8表达下调;在盐胁迫下PR2和PR3表达上调,而PR1a、PR5、PR8和PR16表达下调．另外,对这些PR 基因的上游启动子区进行分析,发现存在与胁迫响应相关的调控元件,其中脱落酸反应元件(ABRE)、TC-rich repeats和HSE的出现频率较高．这些蛋白质表达数据进一步佐证了PR蛋白在逆境胁迫反应中发挥着重要且不尽相同的作用．     

SNRPA1对肝癌的成瘤性的调控机制

小核核糖核蛋白(small nuclear ribonucleoprotein polypeptide A,SNRPA1)参与mRNA加工剪接体(splicesome)的组装,与多种肿瘤的发生有关,但在肝癌发生发展过程中的分子机制尚不明确。该研究利用基因芯片技术探究SNRPA1敲减后肝癌细胞信号通路关键基因的表达动态,及其在裸鼠肿瘤发生发展中的分子机制。研究结果显示,与对照组相比,SNRPA1基因敲减后的低表达组裸鼠的荷瘤细胞的生长受到显著抑制;基因芯片分析表明,SNRPA1的敲低导致462个基因的表达下调,262个基因的表达上调。qRT-PCR分析表明,FSTL1、FGF2、JAK2、WNT5A和PPM1A基因表达均有所降低,而Western blot分析进一步证实FSTL1、JAK2、WNT5A蛋白质表达的下调。以上结果可知,SNPRA1作为促癌基因,可能通过调控多种基因的表达及信号通路对肝细胞肝癌的发生和发展进行调控。     

Cyclic Strain Alters the Expression and Release of Angiogenic Factors by Human Tendon Cells

Angiogenesis is associated with the tissue changes underlying chronic overuse tendinopathy. We hypothesized that repetitive, cyclic loading of human tendon cells would lead to increased expression and activity of angiogenic factors. We subjected isolated human tendon cells to overuse tensile loading using an in vitro model (1 Hz, 10% equibiaxial strain). We found that mechanically stimulated human tendon cells released factors that promoted in vitro proliferation and tube formation by human umbilical vein endothelial cells (HUVEC). In response to cyclic strain, there was a transient increase in the expression of several angiogenic genes including ANGPTL4, FGF-2, COX-2, SPHK1, TGF-alpha, VEGF-A and VEGF-C, with no change in anti-angiogenic genes (BAI1, SERPINF1, THBS1 and 2, TIMP1-3). Cyclic strain also resulted in the extracellular release of ANGPTL4 protein by tendon cells. Our study is the first report demonstrating the induction of ANGPTL4 mRNA and release of ANGPTL4 protein in response to cyclic strain. Tenocytes may contribute to the upregulation of angiogenesis during the development of overuse tendinopathy.     

Correlation of MicroRNA-16, MicroRNA-21 and MicroRNA-101 Expression with Cyclooxygenase-2 Expression and Angiogenic Factors in Cirrhotic and Noncirrhotic Human Hepatocellular Carcinoma

Background

Hepatocellular carcinoma (HCC) is a classical example of inflammation-linked cancer and is characterized by hypervascularity suggesting rich angiogenesis. Cycloxygenase-2 (COX-2) is a potent mediator of inflammation and is considered to upregulate angiogenesis. The aims of the study are (1) to analyze expression of Cox-2 mRNA, Cox-2 protein, miR-16, miR-21 and miR-101 in HCC and adjacent liver parenchyma in cirrhotic and noncirrhotic liver, (2) to investigate the relation between COX-2 expression, miR-21 expression and angiogenic factors in these tissues and (3) to investigate the association between miR-16 and miR-101 and COX-2 expression.

Methods

Tissue samples of HCC and adjacent liver parenchyma of 21 noncirrhotic livers and 20 cirrhotic livers were analyzed for COX-2 expression at the mRNA level (qRT-PCR) and at the protein level by Western blot and immunohistochemistry. Gene expression of VEGFA, VEGFR1, VEGFR2, Ang-1, Ang-2 and Tie-2 were correlated with COX-2 levels. miR-16, miR-21 and miR-101 gene expression levels were quantified in HCC tumor tissue.

Results

COX-2 mRNA and protein levels were lower in HCC as compared to adjacent liver parenchyma both in cirrhotic and noncirrhotic liver. COX-2 protein localized mainly in vascular and sinusoidal endothelial cells and in Kupffer cells. At the mRNA level but not at the protein level, COX-2 correlated with mRNA levels of angiogenic factors VEGFR1, Ang-1, and Tie2. miR-21 expression was higher in cirrhotic tissues versus noncirrhotic tissues. MiR-101 expression was lower in cirrhotic versus noncirrhotic adjacent liver parenchyma. None of the miRNAs correlelated with COX-2 expression. miR-21 correlated negatively with Tie-2 receptor in adjacent liver parenchyma.

Conclusions

In human HCC, COX-2 mRNA but not COX-2 protein levels are associated with expression levels of angiogenic factors. MiR-21 levels are not associated with angiogenic molecules. MiR-16 and miR-101 levels do not correlate with COX-2 mRNA and protein levels.     

Toxicity and anti-angiogenicity evaluation of Pak1 inhibitor IPA-3 using zebrafish embryo model

p21-activated kinase 1 (Pak1)—a key node protein kinase regulating various cellular process including angiogenesis—has been recognised to be a therapeutic target for multitude of diseases, and hence, various small molecule inhibitors targeting its activity have been tested. However, the direct toxic and anti-angiogenic effects of these pharmacologic agents have not been examined. In this study, we evaluate the translational efficacy of Pak1 inhibitor IPA-3 using zebrafish toxicity model system to stratify its anti-angiogenic potential and off-target effects to streamline the compound for further therapeutic usage. The morphometric analysis has shown explicit delay in hatching, tail bending, pericardial sac oedema and abnormal angiogenesis. We provide novel evidence that Pak1 inhibitor could act as anti-angiogenic agents by impeding the development of sub-intestinal vessel (SIV) and intersegmental vessels (ISVs) by suppressing the expression of vascular endothelial growth factor (VEGF), VEGF receptor 2 (VEGFR2), neurophilin 1 (NRP1) and its downstream genes matrix metalloproteinase (MMP)-2 and MMP-9. Knockdown studies using 2-O-methylated oligoribonucleotides targeting Pak1 also revealed similar phenotypes with inhibition of angiogenesis accompanied with deregulation of major angiogenic factor and cardiac-specific genes. Taken together, our findings indicate that Pak1 signalling facilitates enhanced angiogenesis and also advocated the design and use of small molecule inhibitors of Pak1 as potent anti-angiogenic agents and suggest their utility in combinatorial therapeutic approaches targeting anomalous angiogenesis.     

Glucocorticoid effects on angiogenesis are associated with mTOR pathway activity

Glucocorticoids (GC) often are administered during pregnancy, but despite their widespread use in clinical practice, it remains uncertain how GC exposure affects pro-angiogenic factors and their receptors. We investigated the effects of GC on vascular endothelial growth factor (VEGF), placental growth factor (PIGF), vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) protein and mRNA expressions and investigated the possible association of GC with the Akt/mTOR pathway. We incubated human umbilical vein endothelial cells (HUVECs) with a synthetic GC, triamcinolone acetonide (TA). TA administration caused decreased cellular and soluble VEGF and VEGFR1 protein expressions and increased soluble VEGFR2 expression. VEGF, VEGFR1 and VEGFR2 mRNA expressions were altered in a time and dose dependent manner. PIGF protein expression was unaffected by TA treatment, but PIGF mRNA expression decreased in a dose dependent manner after incubation for 48 and 72 h. Phospho-mTOR and phospho-Akt expressions were unaffected. Phospho-p70S6K and phospho-4EBP1 protein expressions and the vascular network forming capacity of HUVECs decreased in a dose dependent manner. We found that GC exert detrimental effects on angiogenesis by altering cellular and soluble angiogenic protein and mRNA levels, and vascular network forming capacities by the Akt/mTOR pathway.     

Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms: A NOVEL THERAPEUTIC STRATEGY FOR ANGIOGENESIS*

Vascular endothelial growth factor (VEGF) is produced either as a pro-angiogenic or anti-angiogenic protein depending upon splice site choice in the terminal, eighth exon. Proximal splice site selection (PSS) in exon 8 generates pro-angiogenic isoforms such as VEGF₁₆₅, and distal splice site selection (DSS) results in anti-angiogenic isoforms such as VEGF₁₆₅b. Cellular decisions on splice site selection depend upon the activity of RNA-binding splice factors, such as ASF/SF2, which have previously been shown to regulate VEGF splice site choice. To determine the mechanism by which the pro-angiogenic splice site choice is mediated, we investigated the effect of inhibition of ASF/SF2 phosphorylation by SR protein kinases (SRPK1/2) on splice site choice in epithelial cells and in in vivo angiogenesis models. Epithelial cells treated with insulin-like growth factor-1 (IGF-1) increased PSS and produced more VEGF₁₆₅ and less VEGF₁₆₅b. This down-regulation of DSS and increased PSS was blocked by protein kinase C inhibition and SRPK1/2 inhibition. IGF-1 treatment resulted in nuclear localization of ASF/SF2, which was blocked by SPRK1/2 inhibition. Pull-down assay and RNA immunoprecipitation using VEGF mRNA sequences identified an 11-nucleotide sequence required for ASF/SF2 binding. Injection of an SRPK1/2 inhibitor reduced angiogenesis in a mouse model of retinal neovascularization, suggesting that regulation of alternative splicing could be a potential therapeutic strategy in angiogenic pathologies.     

The ratio of VEGF/PEDF expression in bone marrow mesenchymal stem cells regulates neovascularization

Angiogenesis, or neovascularization, is a finely balanced process controlled by pro- and anti-angiogenic factors. Vascular endothelial growth factor (VEGF) is a major pro-angiogenic factor, whereas pigment epithelial-derived factor (PEDF) is the most potent natural angiogenesis inhibitor. In this study, the regulatory role of bone marrow stromal cells (BMSCs) during angiogenesis was assessed by the endothelial differentiation potential, VEGF/PEDF production and responses to pro-angiogenic and hypoxic conditions. The in vivo regulation of blood vessel formation by BMSCs was also explored in a SCID mouse model. Results showed that PEDF was expressed more prominently in BMSCs compared to VEGF. This contrasted with human umbilical vein endothelial cells (HUVECs) where the expression of VEGF was higher than that of PEDF. The ratio of VEGF/PEDF gene expression in BMSCs increased when VEGF concentration reached 40ng/ml in the culture medium, but decreased at 80ng/ml. Under CoCl(2)-induced hypoxic conditions, the VEGF/PEDF ratio of BMSCs increased significantly in both normal and angiogenic culture media. There was no expression of endothelial cell markers in BMSCs cultured in either pro-angiogenic or hypoxia culture conditions when compared with HUVECs. The in vivo study showed that VEGF/PEDF expression closely correlated with the degree of neovascularization, and that hypoxia significantly induced pro-angiogenic activity in BMSCs. These results indicate that, rather than being progenitors of endothelial cells, BMSCs play an important role in regulating the neovascularization process, and that the ratio of VEGF and PEDF may, in effect, be an indicator of the pro- or anti-angiogenic activities of BMSCs.     

Angiogenic Expression Profile of Normal and Neurofibromin-Deficient Human Schwann Cells

Peripheral nerve sheath tumors from individuals with Neurofibromatosis Type 1 (NF1) are highly vascular and contain Schwann cells which are deficient in neurofibromin. This study examines the angiogenic expression profile of neurofibromin-deficient human Schwann cells relative to normal human Schwann cells, characterizing both pro-angiogenic and anti-angiogenic factors. Conditioned media from neurofibromin-deficient Schwann cell lines was pro-angiogenic as evidenced by its ability to stimulate endothelial cell proliferation and migration. Using gene array and protein array analysis, we found increased expression of pro-angiogenic factors and decreased expression of anti-angiogenic factors in neurofibromin-deficient Schwann cells relative to normal human Schwann cells. Neurofibromin-deficient Schwann cells also showed increased expression of several growth factor receptors and decreased expression of an integrin. We conclude that neurofibromin-deficient Schwann cells have dysregulated expression of pro-angiogenic factors, anti-angiogenic factors, growth factor receptors, and an integrin. These dysregulated molecules may contribute to the growth and progression of NF1 peripheral nerve sheath tumors.     

肿瘤相关基因表达检测寡核苷酸芯片的制备及其初步应用

为研制肿瘤相关寡核苷酸芯片,并实现其在抗肿瘤反义核酸“癌泰得”作用机理研究方面的初步应用,制备了包含近450种肿瘤相关基因特异寡核苷酸探针的寡核苷酸芯片,建立了相应的质控标准.“癌泰得”用脂质体转染HepG2肿瘤细胞,提取细胞总RNA反转录并荧光标记cDNA,用制备的寡核苷酸芯片检测肝癌细胞HepG2的肿瘤相关基因表达水平,用软件分析获得其差异基因表达谱.0.4 μmol/L的反义核酸“癌泰得”作用于HepG2细胞15 h后,MDNCF、DHS等基因mRNA表达下调,MUC2、MPP11、LAT、HRIF-B、JNK3A1等mRNA基因表达上调,初步检测到了“癌泰得”的抗肿瘤作用可能的相关基因,为进一步的分子作用机理的探讨奠定基础.结果表明,制备的肿瘤相关芯片敏感度高、特异性高、重复性均较好,可用于检测肿瘤相关基因的表达谱,为临床诊断和基础研究提供了技术平台.     

Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins

Altered angiogenesis response is observed in patients with cervical cancer. In this study we examined whether Human Papilloma Virus (HPV) positive epithelial cells are able to produce angiogenic modulators. When added to human umbilical vein endothelial cells (HUVEC) the media conditioned by HPV-16 positive cells was able to induce proliferation, whereas a contrary effect was observed for media derived from non-tumorigenic keratinocytes. The analyses of angiogenesis modulator's mRNA levels result in a decrease of the antiangiogenic factors TSP-1 and 2 in HPV-16 positive cells. In contrast the expression of the pro-angiogenic molecules: bFGF, IL-8, TGF-beta, TNFalpha, and VEGF were higher in these cells as compared to control keratinocytes. Furthermore the pattern of VEGF isoforms observed in the cells positive for the viral genome point to a preferential induction of the VEGF(189) isoform. We therefore conclude that cervical cancer cells expressing HPV-16 genome are able to contribute to the pro-angiogenic response that might support tumor growth and invasion of the surrounding tissues.